Latest Medicinal Cannabis News

Little Green Pharma Ltd (ASX: LGP) has proposed a full acquisition of Cannatrek Ltd via a scheme of arrangement, creating a vertically integrated medicinal cannabis group with pro forma FY26 revenues exceeding AUD 100 million. The scheme, supported by an independent expert, offers liquidity and strategic growth opportunities amid regulatory and market risks.

ECS Botanics has reported a return to profitability and positive cash flow in the first half of FY26, driven by a strategic shift to branded products and major infrastructure expansion.

Little Green Pharma has entered a $7.8 million sale and leaseback agreement for its Western Australia production site, aiming to fuel growth in Australia and Europe while maintaining operational control.

ECS Botanics has partnered with Nimbus Health to distribute its medicinal cannabis products across Germany, marking its entry into Europe's largest cannabis market. The launch of the OzSun brand is set for April 2026, with premium Terphogz strains to follow later in the year.

Little Green Pharma Ltd is set to acquire Cannatrek Ltd in a transformative merger that will create one of the largest vertically integrated medicinal cannabis companies globally, with pro-forma FY25 revenue exceeding AUD 112 million.

Little Green Pharma reports record quarterly revenue and announces a transformative merger with Cannatrek, creating a leading vertically integrated medicinal cannabis group with strong European growth prospects.

Little Green Pharma Ltd has agreed to acquire Cannatrek Ltd in a transformational merger that will create a leading vertically integrated medicinal cannabis group across Australia and Europe. The deal combines cultivation, manufacturing, distribution, clinics, and digital health platforms under one roof, positioning the combined entity for accelerated growth.

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.

Little Green Pharma welcomes a landmark US Executive Order directing cannabis rescheduling, a move poised to reshape the global medicinal cannabis landscape.

Cann Group Limited has launched a comprehensive suite of option offers aimed at raising incremental capital, subject to shareholder approval at a December 23 meeting. The prospectus outlines potential dilution and financial impacts as the company seeks to strengthen its balance sheet.

ECS Botanics is strategically preparing for entry into the US medicinal cannabis market, leveraging its EU-GMP certification and proprietary genetics amid evolving regulatory landscapes.

Bioxyne Limited has secured a pioneering manufacturing and supply agreement to enter the emerging medicinal cannabis markets of Costa Rica and Panama, positioning itself as a first mover with promising revenue potential.